<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="233">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00001981</url>
  </required_header>
  <id_info>
    <org_study_id>850082</org_study_id>
    <secondary_id>85-DK-0082</secondary_id>
    <nct_id>NCT00001981</nct_id>
  </id_info>
  <brief_title>The Treatment and Natural History of Acromegaly</brief_title>
  <official_title>Acromegaly Treatment and Natural History</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the treatment and natural history of acromegaly.
       We have a longstanding interest in acromegaly treatment, and a cohort that has been
      followed for 30 years, or more in some cases.  We will continue to follow patients and
      recruit new patients for treatment and follow-up.  Blood and pituitary tumor tissue (when
      available through clinical care) will be saved for future analyses related to acromegaly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the treatment and natural history of acromegaly.
       We have a longstanding interest in acromegaly treatment, and a cohort that has been
      followed for 30 years, or more in some cases.  We will continue to follow patients and
      recruit new patients for treatment and follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 1985</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <enrollment type="Anticipated">99999999</enrollment>
  <condition>Acromegaly</condition>
  <condition>Pituitary Neoplasm</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients will be enrolled who are 18 years of age or over who are referred for care.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Gorden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig S Cochran, R.N.</last_name>
    <phone>(301) 402-1880</phone>
    <email>craigc@bdg10.niddk.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phillip Gorden, M.D.</last_name>
    <phone>(301) 402-7340</phone>
    <email>gordenp@extra.niddk.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@mail.cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1985-DK-0082.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712. Review.</citation>
    <PMID>1521519</PMID>
  </reference>
  <reference>
    <citation>Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35-50. Review.</citation>
    <PMID>2535688</PMID>
  </reference>
  <reference>
    <citation>Eastman RC, Arakaki RF, Shawker T, Schock R, Roach P, Comi RJ, Gorden P. A prospective examination of octreotide-induced gall-bladder changes in acromegaly. Clin Endocrinol (Oxf). 1992 Mar;36(3):265-9.</citation>
    <PMID>1563079</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>January 21, 2000</firstreceived_date>
  <keyword>Somatostatin Analogue</keyword>
  <keyword>Acromegaly</keyword>
  <keyword>TSH Producing Tumor</keyword>
  <keyword>Islet Cell Tumor</keyword>
  <keyword>Ursodeoxycholate</keyword>
  <keyword>Pituitary</keyword>
  <keyword>Irradiation</keyword>
  <keyword>Treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
